Moustafa Abdou/LinkedIn
Aug 21, 2026, 12:42
Moustafa Abdou: Diagnosis and Management of Pyruvate Kinase Deficiency
Moustafa Abdou, Author and Founder of AskHematologist.com, shared a post on LinkedIn:
”Not every chronic haemolytic anaemia is immune-mediated.
Pyruvate kinase deficiency (PKD) is a rare inherited red-cell enzyme disorder that can remain unrecognised for years, with presentations ranging from severe neonatal jaundice to compensated haemolytic anaemia in adulthood.
In my updated clinical review, I discuss:
- Clinical presentation and complications
- Diagnostic and laboratory approach
- PKLR genetics and pathophysiology
- Current treatment strategies
- The emerging role of mitapivat, a pyruvate kinase activator
Key clinical message: Consider PK deficiency in patients with unexplained chronic haemolysis, particularly when immune and other common causes have been excluded.”
Other posts featuring Moustafa Abdou on Hemostasis Today.
-
Aug 21, 2026, 12:57David McIntosh: Why Do Blood Supplies Still Fall Short?
-
Aug 21, 2026, 12:48Joshua Penrod: 35 Years of Progress in Plasma Safety
-
Aug 21, 2026, 12:38Luluva Ghadiyali: Modern Approaches to Aplastic Anemia
-
Aug 21, 2026, 12:34Kellie Machlus: Animal Models Driving Progress in Thrombosis Research
-
Aug 21, 2026, 12:08Amy Allen Whitfield: Helping to Proceed Bleeding Disorders Care
-
Aug 21, 2026, 11:53Jan Terje Andersen: Harnessing Placental Biology for Therapeutic Engineering
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029
-
Aug 21, 2026, 10:42Janine Mothershed: What Is Romiplostim and How Does It Work in Immune Thrombocytopenia?